Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 4.72 |
|---|---|
| High | 5.25 |
| Low | 4.72 |
| Bid | 5.25 |
| Offer | 5.35 |
| Previous close | 3.84 |
| Average volume | 0.00 |
|---|---|
| Shares outstanding | 43.27m |
| Free float | 41.72m |
| P/E (TTM) | -- |
| Market cap | 273.06m USD |
| EPS (TTM) | -1.85 USD |
Data delayed at least 15 minutes, as of Feb 10 2026.
More ▼
Announcements
- Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026
- Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors
- Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates
- Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved
- Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results
- Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates
- Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates
More ▼
